Dose increase augments response rate to interferon-α in chronic hepatitis C

Publisher Website
Google Scholar
Abstract
Approximately 50% of patients with chronic hepatitis C respond to treatment with interferon-α. The aim of this randomized controlled trial was to evaluate whether an increase in dose of interferon-α augments response rate. One hundred thirty-eight patients with newly diagnosed chronic hepatitis C received a three-month course of 3 MU IFN-α2b administered every two days. All patients were anti-HCV and HCV-RNA (PCR) positive. Prior to treatment, a liver biopsy was performed. Complete response was defined by normal serum ALT concentrations and disappearance of HCV-RNA. After three months, 60 nonresponders were randomized (stratified according to histology) either to continue 3 MU interferon-α2b every two days for another six months (group A, total dose: 410 MU) or to receive increasing doses of interferon-α2b (6 MU every two days for three months, followed by 10 MU every two days for three months) (group B, total dose: 870 MU). Serum ALT concentrations were measured monthly and HCV-RNA at three-month intervals. Liver biopsy was repeated six months after end of treatment. Pretreatment characteristics of the randomized patients were: group A:N=30; male/female: 20/10; age: 54±10 years; CPH 9, CAH 8, cirrhosis 13; mean ALT 108±98 units/liter; group B:N=30; male/female: 21/9; age: 57±15 years; CPH 10, CAH 9, cirrhosis 11; mean ALT 90±40 units/liter. At the end of treatment six patients in group B but none in group A became responders [P=0.011 (Fisher's exact test), intent-to-treat analysis]. All six responders were noncirrhotics. High-dose interferon was not tolerated by six patients in group B. Noncompliance resulted in five dropouts in group A and one in group B. During the six-month follow-up, four of the six responders relapsed. A patient in group A with increased serum ALT concentration but negative HCV-RNA at the end of treatment became a full responder after six months. Of nonresponders to 3 MU interferon α2b every two days for three months, 20% responded to higher interferon doses, but none to continued standard dose. Prolonged treatment with interferon may be necessary to obtain a sustained response. However, treatment with higher-dose interferon was not tolerated in 20% of the patients.